logologo
Search anything
Ctrl+K
arrow
WhatsApp Icon

MPS Limited: Navigating a 'Holding Quarter' with Strategic Acumen and Future Growth in Sight

MPSLTD

MPS Ltd

MPSLTD

Ask AI

Ask AI

MPS Limited, a prominent player in digital learning and content solutions, recently unveiled its financial results for the third quarter (Q3) and nine months (9M) ended December 31, 2025. While Q3 FY26 presented a 'holding quarter' with a marginal year-on-year revenue decline, the underlying narrative points to strategic repositioning, robust core business growth, and a transformative acquisition poised to unlock significant future value. The company's leadership remains confident in achieving a milestone EPS of INR 100+ for the full financial year 2026, underscoring a disciplined approach to growth and operational efficiency.

For Q3 FY26, MPS Limited reported a revenue of INR 182.49 crore, a slight decrease of 2.08% compared to the previous year. Despite this, the core business, excluding Author Journal English (AJE) services, demonstrated resilience with a 6.48% year-on-year growth, reaching INR 153.59 crore. This growth was primarily fueled by continued business expansion and stable customer demand. Profitability metrics, however, saw a contraction, with Profit Before Tax (PBT) declining by 17.03% to INR 45.71 crore and Profit After Tax (PAT) falling by 12.80% to INR 35.50 crore. This was partly influenced by an exceptional item of INR 7.02 crore recognized as a provision for defined benefit obligation due to the New Labour Code. The EBITDA margin stood at 31.55%, well within the company's healthy operational range.

Segmental Performance and Strategic Shifts

The company's revenue mix reflects a balanced yet evolving portfolio. Research Solutions remains the dominant segment, contributing 63.3% of the total revenue in Q3 FY26. Excluding AJE, this core business grew impressively at 16.20% year-on-year, demonstrating strong engagement with key accounts and successful new customer acquisition. Management highlighted a strategic shift towards AI-powered workflows and platform scaling, such as DigiCorePro, to ensure non-linear growth and future-proof the business.

Education Solutions emerged as a standout performer, with its contribution expanding from 21.4% in Q3 FY25 to 24.3% in Q3 FY26. The segment's revenue grew by 11.30% year-on-year to INR 44.33 crore, and its EBITDA increased by 13.65% to INR 18.07 crore, with margins improving to 40.76%. This growth is attributed to a strong order pipeline, an expanding customer base, and continued investment in digital learning, multimedia, and interactive solutions, including AI-assisted production and accessibility frameworks.

Conversely, the Corporate Learning segment experienced a significant pullback, with its contribution moderating from 16.0% in Q3 FY25 to 12.4% in Q3 FY26. This decline reflects a deliberate reset and ongoing restructuring within the business. Management initiated an 'Andon Cord' project focused on radical cost optimization, moving away from low-margin legacy work to realign the segment with broader group growth. The emphasis is now on AI-enabled solutions, immersive (VR/AR) learning, and experiential training, alongside targeted workforce optimization and leadership restructuring to improve cost alignment and execution agility.

Financial Summary (INR Crore)

MetricQ3 FY26Q3 FY25Variance %
Reported Revenue182.49186.36-2.08%
EBITDA57.5860.34-4.57%
PBT45.7155.09-17.03%
PAT35.5040.71-12.80%
EBITDA (%)31.55%32.38%-0.83%
PBT (%)25.05%29.56%-4.51%
PAT (%)19.45%21.84%-2.39%
Basic EPS (INR)20.9324.00-12.79%

Note: PBT for Q3 FY26 includes an exceptional item of INR 7.02 crore recognized as a provision for defined benefit obligation due to the impact of the New Labour Code.

Strategic Acquisition: Unbound Medicine

A pivotal development for MPS Limited is the acquisition of 100% stake in Unbound Medicine, Inc., a U.S.-based healthcare learning technology company, for USD 16.5 million. This acquisition, announced on January 30, 2026, is a transformative step, marking MPS' entry into the high-growth healthcare and medical information technology segment. Unbound Medicine, founded in 1999, provides mobile-first, AI-enabled clinical decision support and medical education platforms, serving over 480 institutional customers with a subscription-led business model and approximately 97% gross retention.

This strategic move aligns with MPS' long-term vision to exceed INR 1,500 crore in revenue by FY28. The acquisition is expected to generate significant value through revenue diversification, cross-selling opportunities, and AI-driven innovation. By integrating Unbound's capabilities, MPS aims to offer a comprehensive portfolio spanning digital content, AI-powered clinical decision support, and institutional learning platforms, positioning itself as a holistic partner across education and healthcare sectors. The company plans to leverage MPS Labs' AI expertise to enhance Unbound's platforms, focusing on multilingual support and domain-specific innovations.

Outlook and Management Confidence

Despite the Q3 challenges, MPS Limited's management expressed strong confidence in the company's future trajectory. They anticipate a better Q4 FY26 and expect FY27 to be an

Frequently Asked Questions

For Q3 FY26, MPS Limited reported a revenue of INR 182.49 crore, a marginal YoY decline of 2.08%. However, revenue excluding AJE grew by 6.48% YoY. PBT declined by 17.03% to INR 45.71 crore, and PAT declined by 12.80% to INR 35.50 crore, partly due to an exceptional item of INR 7.02 crore. The EBITDA margin stood at 31.55%.
Research Solutions remained the dominant segment, contributing 63.3% of revenue, with its core business (excl. AJE) growing 16.20% YoY. Education Solutions was a standout performer, growing 11.30% YoY to INR 44.33 crore. Corporate Learning saw a significant pullback, with its contribution moderating to 12.4%, as it undergoes restructuring.
The acquisition of Unbound Medicine, Inc. for USD 16.5 million marks MPS Limited's strategic entry into the high-growth healthcare and medical information technology segment. Unbound Medicine offers a subscription-led business model with high customer retention, providing predictable recurring revenue and significant cross-selling and AI-driven innovation opportunities for MPS.
Management is confident that MPS Limited is comfortably placed to achieve an EPS of INR 100+ for the first time in FY26.
MPS Limited has initiated a 'disciplined reset' in Corporate Learning, focusing on radical cost optimization, moving away from low-margin legacy work, and emphasizing AI-enabled solutions, immersive learning, and experiential training to drive future margin recovery and scalable growth.
MPS Limited maintains a strong, debt-free balance sheet with total cash and cash equivalents of INR 143 crore as of December 31, 2025. The company plans to use debt as an option for the Unbound Medicine acquisition.

A NOTE FROM THE FOUNDER

Hey, I'm Aaditya, founder of Multibagg AI. If you enjoyed reading this article, you've only seen a small part of what's possible with Multibagg AI. Here's what you can do next:

It's all about thinking better as an investor. Welcome to a smarter way of doing stock market research.